Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy

NCT02514278 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

218

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: Neoadjuvant chemotherapy Folfirinox, 4 cycles
RADIATION: 50 Gy, 2 Gy/session; 25 fractions
PROCEDURE: Local excision in good responders
PROCEDURE: Rectal excision in bad responders
DRUG: Capecitabine

Sponsor

University Hospital, Bordeaux